Advertisement

Glucagon Nasal Powder: Treating Hypoglycemia in Individuals With Diabetes Mellitus

      Highlights

      • Raising glucose quickly is critical in restoring homeostasis and ensuring the well-being of individuals experiencing severe hypoglycemia.
      • Glucagon intramuscular injections have been the standard of care for the treatment of hypoglycemia, but they are difficult for care partners to administer.
      • Glucagon nasal powder offers a relatively new, easy-to-use innovation for treating severe hypoglycemia in those with type 1 or 2 diabetes mellitus.
      • Empirical data suggest glucagon nasal powder is comparable to injectable glucagon regarding its action, half-life, peak, and adverse reactions.

      Abstract

      Individuals who take insulin and some oral glucose-lowering agents for type 1 and 2 diabetes mellitus may experience severe hypoglycemia. Glucagon nasal powder offers a relatively new, easy-to-use innovation for treating severe hypoglycemia in those with type 1 or 2 diabetes mellitus. This brief report provides information nurse practitioners can use in prescribing this medication to individuals with diabetes mellitus who are at risk for severe hypoglycemia and in teaching patients and significant others regarding this medication.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Centers for Disease Control and Prevention
        National Diabetes Statistics Report: coexisting conditions and complications.
        (2021. Accessed 21 April 2022)
        • American Diabetes Association
        Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes—2022.
        Diabetes Care. 2022; 45: S83-S96https://doi.org/10.2337/dc22-S006
        • Singh-Franco D.
        • Moreau C.
        • Levin A.D.
        • Rosa D.
        • Johnson M.
        Efficacy and usability of intranasal glucagon for the management of hypoglycemia in patients with diabetes: a systematic review.
        Clin Ther. 2020; 42: e177-e208https://doi.org/10.1016/j.clinthera.2020.06.024
        • Eli Lilly and Company
        Glucagon.
        https://uspl.lilly.com/glucagon/glucagon.html#pi0
        Date: 2021
        Date accessed: May 18, 2022
        • Xeris Pharmaceuticals
        GVOKE®.
        • Zealand Pharma US
        Inc. ZEGALOGUE—dasiglucagon injection, solution.
        https://medlibrary.org/lib/rx/meds/zegalogue/
        Date: 2022
        Date accessed: April 22, 2022
        • Pontiroli A.E.
        • Tagliabue E.
        Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.
        Acta Diabetol. 2020; 57: 743-749https://doi.org/10.1007/s00592-020-01483-y
        • Mitchell B.D.
        • He X.
        • Sturdy I.M.
        • Cagle A.P.
        • Settles J.A.
        Glucagon prescription patterns in patients with either type 1 or 2 diabetes with newly prescribed insulin.
        Endocr Pract. 2016; 22: 123-135https://doi.org/10.4158/EP15831.OR
        • Drugs.com
        Glucagon prices, coupons and patient assistance programs.
        https://www.drugs.com/price-guide/glucagon
        Date: 2022
        Date accessed: May 24, 2022
        • Goodrx.com
        Glucagon.
        https://www.goodrx.com/glucagon
        Date: 2022
        Date accessed: May 24, 2022
        • Eli Lilly & Company
        Baqsimi ®-glucagon powder.
        https://uspl.lilly.com/baqsimi/baqsimi.html#ug
        Date: 2020
        Date accessed: April 21, 2022
        • Bajpai S.K.
        • Cambron-Mellott M.J.
        • Peck E.
        • et al.
        Perceptions about glucagon delivery devices for severe hypoglycemia: qualitative research with patients, caregivers, and acquaintances.
        Clin Ther. 2019; 41: 2073-2089.e.6https://doi.org/10.1016/j.clinthera.2019.08.006
        • Isaacs D.
        • Clements J.
        • Turco N.
        • Hartman R.
        Glucagon: its evolving role in the management of hypoglycemia.
        Pharmacotherapy. 2021; 41: 623-633https://doi.org/10.1002/phar.2534
      1. Drugs.com. Baqsimi prices, coupons and patient assistance programs.
        https://www.drugs.com/price-guide/baqsimi
        Date: 2022
        Date accessed: May 26, 2022
        • Sherr J.L.
        • Ruedy K.J.
        • Foster N.C.
        • et al.
        T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes.
        Diabetes Care. 2016; 39: 555-562https://doi.org/10.2337/dc15-1606
        • Sherman J.J.
        • Lariccia J.L.
        Glucagon therapy: a comparison of current and novel treatments.
        Diabetes Spectr. 2020; 33: 347-351https://doi.org/10.2337/ds19-0076

      Biography

      Joan S. Grant, PhD, RN, is a professor at the University of Alabama at Birmingham School of Nursing, Birmingham, AL, and can be contacted at [email protected] .

      Biography

      Michele, H. Talley, PhD, ACNP-BC, is an associate professor at the University of Alabama at Birmingham School of Nursing, Birmingham, AL.